As a prototype, our idiotype neoantigen vaccine demonstrated safety, the ability to significantly reduce clonal mature B-cell, but not plasma cell-like, LPL subpopulations and to favorably perturb the tumor microenvironment. Here, LPL is linked to neoplasm.